Prior to testing our ex vivo-derived hypothesis that dual AKT and XPO1 inhibition in AML cell lines would abrogate selinexor resistance, we initially wanted to confirm the global phosphoproteome findings and subsequently screened a panel of nine AML cell lines for selinexor sensitivity and subjected them to the PAFS analytical approach as well. Here, XPO1 is linked to acute myeloid leukemia.